BRAF and neoplasm: By taking advantage of the Lee et al. scRNAseq study (Lee et al., 2020), we derived a tumor-specific signature (CMS4_TC) by selecting epithelial-specific genes from the original CMS4_RF signature that outperforms other commonly employed prognostic and predictive markers (e.g., BRAF mutation and MSI; data not shown) in stratifying CMS1, 3, and 4 colon cancer patients based on overall survival.